Price T Rowe Associates Inc. MD Reduces Position in Lantheus Holdings, Inc. $LNTH

Key Points

• Price T Rowe Associates Inc. MD reduced its position in Lantheus Holdings, Inc. by 9.1%, now owning approximately 1,003,754 shares valued at nearly $98 million.
• Several large investors, including Janus Henderson Group PLC and Farallon Capital Management LLC, significantly increased their stakes in Lantheus, reflecting strong institutional interest in the company.
• Lantheus reported a missed earnings estimate for the last quarter, with EPS of $1.57 compared to the expected $1.65, and revenue of $378.05 million, falling short of the $389.69 million estimate.

Price T Rowe Associates Inc. MD lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,003,754 shares of the medical equipment provider's stock after selling 100,283 shares during the period. Price T Rowe Associates Inc. MD owned 1.47% of Lantheus worth $97,967,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LNTH. Janus Henderson Group PLC grew its stake in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after acquiring an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its stake in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. TD Asset Management Inc boosted its holdings in Lantheus by 1,028.0% in the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock valued at $66,623,000 after purchasing an additional 622,100 shares during the last quarter. Nuveen LLC acquired a new position in Lantheus in the 1st quarter valued at about $55,941,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock valued at $32,817,000 after purchasing an additional 310,301 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $56.16 on Tuesday. The firm's 50 day moving average price is $71.04 and its 200-day moving average price is $83.96. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The firm has a market cap of $3.82 billion, a P/E ratio of 14.94 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). The company had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business's revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.80 earnings per share. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the topic of several recent analyst reports. Truist Financial set a $63.00 target price on shares of Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. JMP Securities decreased their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Finally, Mizuho decreased their target price on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $105.50.

Insiders Place Their Bets

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,838,066 shares of company stock worth $384,430,031 in the last ninety days. 2.00% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.